On the spring of last year, diphosphopyridine nucleotide (DPN or NAD, coenzyme I of the cellular oxidation-reduction systems) was claimed to be effective in short-term treatment of schizophrenia.1 This method of treatment was based on the results of studies showing the purported beneficial effect of long-term administration of niacin (nicotinic acid, a constituent of the vitamin B complex) or its derivative niacinamide in schizophrenia.2,3 Since niacinamide is an integral part of the coenzyme, it was suggested that these therapeutic effects were exerted by diphosphopyridine nucleotide and could readily be elicited by administering 1 to 2 gm of this preparation orally; 75% of the treated cases were said to show undeniable improvement five to seven days after the beginning of treatment.1
Our evaluation of diphosphopyridine for the treatment of patients with chronic schizophrenia who were residing in our research ward will be reported in full in a speciality
Kline NS, Barclay GL, Esser AH, Cole JO, Lehmann HE, Wittenborn JR. Diphosphopyridine Nucleotide in the Treatment of Schizophrenia. JAMA. 1967;200(10):881–882. doi:10.1001/jama.1967.03120230133021
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: